VRTX vs. AMGN, REGN, GILD, AGN, ALXN, ALNY, BIIB, BGNE, RPRX, and BMRN
Should you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Amgen (AMGN), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), Allergan (AGN), Alexion Pharmaceuticals (ALXN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BeiGene (BGNE), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN).
Vertex Pharmaceuticals (NASDAQ:VRTX) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations.
Vertex Pharmaceuticals received 39 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 75.61% of users gave Vertex Pharmaceuticals an outperform vote while only 72.38% of users gave Amgen an outperform vote.
In the previous week, Amgen had 11 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 22 mentions for Amgen and 11 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.10 beat Amgen's score of 0.85 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.
Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Vertex Pharmaceuticals currently has a consensus target price of $485.91, suggesting a potential upside of 0.11%. Amgen has a consensus target price of $327.28, suggesting a potential downside of 1.56%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Vertex Pharmaceuticals is more favorable than Amgen.
Amgen has a net margin of 10.12% compared to Vertex Pharmaceuticals' net margin of -4.74%. Amgen's return on equity of 161.72% beat Vertex Pharmaceuticals' return on equity.
91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Vertex Pharmaceuticals has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.
Summary
Vertex Pharmaceuticals and Amgen tied by winning 9 of the 18 factors compared between the two stocks.
Get Vertex Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vertex Pharmaceuticals Competitors List
Related Companies and Tools
